ID

36564

Descripción

Open-label, Multi-Centre Trial Investigating Pharmacokinetics of Degarelix After a Starting Dose of 240 mg (40 mg/mL) Followed by Six Maintenance Doses of 80 mg (20 mg/mL) in Chinese Patients With Prostate Cancer Requiring Androgen Deprivation Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT02468284

Link

https://clinicaltrials.gov/show/NCT02468284

Palabras clave

Versiones (2)
  1. 19/1/19 19/1/19 -
  2. 22/5/19 22/5/19 -
Titular de derechos de autor

Ferring Pharmaceuticals

Subido en

22 de mayo de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

  • El más nuevo
  • Más antiguo
  • Popular
  • El más nuevo
    • El más nuevo
    • Más antiguo
    • Popular

Sin comentarios

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Pharmacokinetics of Degarelix in Prostate Cancer NCT02468284

Inglés

Eligibility Criteria

1 formularios  
  1. StudyEvent: Eligibility
    1. Eligibility Criteria
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
has a histologically confirmed (gleason graded) adenocarcinoma of the prostate (all stages), for which endocrine therapy (except for neoadjuvant hormonal therapy) is indicated
Descripción

Histologically confirmed (gleason graded) adenocarcinoma of prostate for which endocrine therapy (except neoadjuvant hormonal therapy) is indicated

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0679557
UMLS CUI [1,2]
C0007112
UMLS CUI [2]
C0332326
UMLS CUI [3,1]
C3146298
UMLS CUI [3,2]
C0279025
UMLS CUI [4,1]
C2828389
UMLS CUI [4,2]
C0279025
UMLS CUI [4,3]
C0600558
has a prostate-specific antigen (PSA) level ≥2.0 ng/ml at screening
Descripción

PSA level

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0201544
has a screening serum testosterone level >150 ng/dl
Descripción

serum testosterone level

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0428413
has an eastern cooperative oncology group (ECOG) score of ≤2
Descripción

ECOG score

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
has had previous or is currently under hormonal management of prostate cancer. however, hormonal therapy for a maximum duration of 6 months is accepted. this treatment should have been terminated at least 6 months prior to the screening visit
Descripción

previous or current hormonal management of prostate cancer

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0007112
UMLS CUI [1,2]
C0279025
UMLS CUI [1,3]
C0521116
UMLS CUI [2,1]
C0332185
UMLS CUI [2,2]
C0007112
UMLS CUI [2,3]
C0279025
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0205156
UMLS CUI [3,3]
C0871548
UMLS CUI [3,4]
C0279025
UMLS CUI [3,5]
C0439801
UMLS CUI [3,6]
C0449238
is currently treated with a 5-alpha reductase inhibitor
Descripción

currently treated with a 5-alpha reductase inhibitor

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1318898
UMLS CUI [1,2]
C0521116
is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy
Descripción

considered a candidate for curative therapy, i.e. radical prostatectomy or radiotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0332149
UMLS CUI [1,2]
C1273390
UMLS CUI [2]
C0194810
UMLS CUI [3]
C1522449
is in need of neoadjuvant hormonal therapy
Descripción

in need of neoadjuvant hormonal therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3146298
UMLS CUI [1,2]
C0279025
UMLS CUI [1,3]
C0600558
has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy
Descripción

history of bilateral orchiectomy, adrenalectomy, or hypophysectomy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0262926
UMLS CUI [1,2]
C0194875
UMLS CUI [2,1]
C0262926
UMLS CUI [2,2]
C0001632
UMLS CUI [3,1]
C0262926
UMLS CUI [3,2]
C0020632
Volver a la parte superior de la página

Similar models

Eligibility Criteria

1 formularios
  1. StudyEvent: Eligibility
    1. Eligibility Criteria
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Histologically confirmed (gleason graded) adenocarcinoma of prostate for which endocrine therapy (except neoadjuvant hormonal therapy) is indicated
Item
has a histologically confirmed (gleason graded) adenocarcinoma of the prostate (all stages), for which endocrine therapy (except for neoadjuvant hormonal therapy) is indicated
boolean
C0679557 (UMLS CUI [1,1])
C0007112 (UMLS CUI [1,2])
C0332326 (UMLS CUI [2])
C3146298 (UMLS CUI [3,1])
C0279025 (UMLS CUI [3,2])
C2828389 (UMLS CUI [4,1])
C0279025 (UMLS CUI [4,2])
C0600558 (UMLS CUI [4,3])
PSA level
Item
has a prostate-specific antigen (PSA) level ≥2.0 ng/ml at screening
boolean
C0201544 (UMLS CUI [1])
serum testosterone level
Item
has a screening serum testosterone level >150 ng/dl
boolean
C0428413 (UMLS CUI [1])
ECOG score
Item
has an eastern cooperative oncology group (ECOG) score of ≤2
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
previous or current hormonal management of prostate cancer
Item
has had previous or is currently under hormonal management of prostate cancer. however, hormonal therapy for a maximum duration of 6 months is accepted. this treatment should have been terminated at least 6 months prior to the screening visit
boolean
C0007112 (UMLS CUI [1,1])
C0279025 (UMLS CUI [1,2])
C0521116 (UMLS CUI [1,3])
C0332185 (UMLS CUI [2,1])
C0007112 (UMLS CUI [2,2])
C0279025 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C0205156 (UMLS CUI [3,2])
C0871548 (UMLS CUI [3,3])
C0279025 (UMLS CUI [3,4])
C0439801 (UMLS CUI [3,5])
C0449238 (UMLS CUI [3,6])
currently treated with a 5-alpha reductase inhibitor
Item
is currently treated with a 5-alpha reductase inhibitor
boolean
C1318898 (UMLS CUI [1,1])
C0521116 (UMLS CUI [1,2])
considered a candidate for curative therapy, i.e. radical prostatectomy or radiotherapy
Item
is considered to be candidate for curative therapy, i.e. radical prostatectomy or radiotherapy
boolean
C0332149 (UMLS CUI [1,1])
C1273390 (UMLS CUI [1,2])
C0194810 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
in need of neoadjuvant hormonal therapy
Item
is in need of neoadjuvant hormonal therapy
boolean
C3146298 (UMLS CUI [1,1])
C0279025 (UMLS CUI [1,2])
C0600558 (UMLS CUI [1,3])
history of bilateral orchiectomy, adrenalectomy, or hypophysectomy
Item
has a history of bilateral orchiectomy, adrenalectomy, or hypophysectomy
boolean
C0262926 (UMLS CUI [1,1])
C0194875 (UMLS CUI [1,2])
C0262926 (UMLS CUI [2,1])
C0001632 (UMLS CUI [2,2])
C0262926 (UMLS CUI [3,1])
C0020632 (UMLS CUI [3,2])
Volver a la parte superior de la página 

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial